Imugene Secures Funding Amid Promising Clinical Trial Data

Imugene secures $20M AUD to expand trials for azer-cel, its off-the-shelf CAR-T therapy, after reporting 100% response rate in early CLL/SLL patients.

The clinical-stage biopharmaceutical company Imugene has successfully raised 20 million Australian dollars to advance its lead immunotherapy candidate. This strategic financing arrives concurrently with the release of encouraging early clinical results for its "off-the-shelf" CAR-T cell therapy, azer-cel, in treating certain blood cancers.

Fresh Capital to Fuel Clinical Expansion

To support its development pipeline, Imugene initiated a two-part financing round. The primary component involved a placement to institutional investors, raising 12 million AUD. Shares were offered at a price of 0.18 AUD each, representing a 21.7% discount to the last closing price before the announcement. Complementing this, an 8 million AUD share purchase plan (SPP) was made available to existing shareholders under similar terms. At the launch of this capital measure, Imugene's market capitalization stood at approximately 74 million AUD.

The newly acquired funds are earmarked to accelerate patient recruitment and broaden clinical activities for azer-cel. The therapy is currently under investigation at ten clinical sites in the United States and five within Australia.

Compelling Early Efficacy Signals

The capital raise is bolstered by positive interim data from the ongoing Phase 1b study of azer-cel. In the cohort evaluating patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), an overall response rate (ORR) of 100% was observed. All four evaluable patients, who had undergone a median of three or more prior lines of therapy, achieved a partial remission.

Promising results were also recorded in patients with marginal zone lymphoma (MZL), where the response rate reached 80%. Among five assessed subjects, three attained a complete remission and one achieved a partial remission. These participants had previously received a median of two or more therapy lines.

Study Protocol Enhanced Following Positive Readouts

In response to these encouraging interim outcomes, Imugene is expanding the scope of its clinical trial. The company is adding a new cohort for patients with mantle cell lymphoma (MCL). Furthermore, a separate study arm will investigate combining azer-cel with BTK inhibitors, a strategy aimed at potentially enhancing efficacy for heavily pre-treated patients.

The company's approach centers on an "off-the-shelf" platform technology, designed to circumvent the logistical complexities associated with traditional personalized CAR-T cell therapies. Investor attention in the coming months will likely focus on whether the high response rates can be sustained and validated within these broader patient groups.